Quince Therapeutics Inc expected to post a loss of 23 cents a share - Earnings Preview

IRulya Therapeutics

09/05/2025 16:10

Quince Therapeutics Inc QNCX.OQ QNCX.O is expected to show no change in quarterly revenue when it reports  results on May 12 (estimated) for the period ending March 31 2025

​LSEG's mean analyst estimate for Quince Therapeutics Inc is for a loss of 23 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 1.0% in the last three months. ​

Wall Street's median 12-month price target for Quince Therapeutics Inc is $7.50​, above​ its last closing price of $1.03. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
-0.18
-0.17
-0.28
Missed
-60
Sep. 30 2024
-0.16
-0.21
-0.13
Beat
38.1
-0.64
​
-0.26
​​
​

This summary was machine generated May 9 at 15:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)